Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MI226 in Abdominal Fat Accumulation
NCT07749742Phase 1Recruiting
- Sponsor
- Nanjing Minova Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in abdominal obesity comparing MI226 Injection with Placebo (2 arms). Primary endpoints: Incidence and severity of treatment-emergent adverse events at 28 days, Number of participants with clinically significant abnormal physical examination findings at 28 days and 3 more. Started Jul 2026; status: recruiting.
02
Drugs
MI226
03
Conditions
abdominal obesity
Beyond the preview
Go deeper on NCT07749742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07749742.